AtheroGenics, Inc.{AGIX}-nasdaq Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Secret_Agent_Man who started this subject	2/21/2001 8:10:19 PM
From: sim1	of 332

AtheroGenics, Inc. (Nasdaq: AGIX) $6.75 Buy Jay Silverman, Biopharmaceuticals "AtheroGenics announced that it filed an Investigation New Drug (IND) application to the FDA to begin clinical trials on AGIX-4207, an orally administered compound for rheumatoid arthritis, ahead of schedule," said Silverman. "AtheroGenics expects to begin a Phase I dose escalation study soon, this quarter, on healthy volunteers to assess the safety and tolerability of the new compound. AGIX-4207 is a v-protectant, a proprietary and novel class of compounds being developed by AtheroGenics to fight inflammatory diseases. The v-protectants act by preventing inflammatory cells from migrating from the bloodstream and into the tissues where they can promote inflammation. AGIX-4207 will be AtheroGenics' second compound to enter the clinic, after AGIX-1067, which is being tested for the treatment of restenosis in a Phase II trial that should complete in 2Q:01. We reiterate our Buy rating."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next